BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 19, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

June 4, 2015

View Archived Issues

Dual GHSR-NPY2R targeting peptides show promise for obesity treatment

Read More

QPCT: new druggable target for Huntington's disease identified by siRNA screen

Read More

Novira Therapeutics divulges anti-HBV azepanes

Read More

Biotest and Affibody sign Albumod research license and option agreement

Read More

Ontario Institute for Cancer Research invests in PanCuRx pancreatic cancer initiative

Read More

HTG Molecular Diagnostics and MD Anderson to investigate molecular diagnostics for lung cancer

Read More

German Centre for Infection Research announces clinical investigation of anti-MRSA

Read More

Phase I results reported for the small-molecule glutaminase inhibitor CB-839

Read More

NeoStem to change name to Caladrius Biosciences

Read More

Vitesse Biologics created by Baxter Ventures, Mayo Clinic and Velocity Pharmaceutical Development

Read More

ProLynx cleared to start phase I trial of PEG-SN-38

Read More

Oncolytic virus therapy with recombinant HSV-1 is efficient for NSGCT treatment

Read More

EMA provides guidance on MAA submission for Locilex

Read More

Nektar and MD Anderson Cancer Center to collaborate on phase I/II trials of NKTR-214

Read More

Amgen to collaborate with Roche on phase Ib study of talimogene laherparepvec with atezolizumab

Read More

Neovia Oncology and FDA meet to discuss NEV-801 IND

Read More

RaQualia to begin first-in-human phase I study of RQ-00310941

Read More

Wistar Institute patents EBNA-1 inhibitors

Read More

Catabasis Pharmaceuticals discloses PCSK9 inhibitors

Read More

Pfizer presents EGFR inhibitors

Read More

European Commission approves Akynzeo

Read More

NICE recommends Vargatef for NSCLC in England and Wales

Read More

FDA awards orphan drug designation to ibudilast for Krabbe disease

Read More

Amicus submits MAA seeking full European approval of Galafold for Fabry's disease

Read More

FDA issues letter of support for autosomal dominant polycystic kidney disease biomarker

Read More

Genzyme's olipudase alfa granted FDA breakthrough therapy designation

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Rare disease illustration

    Rare earth: Biomarin to use global reach post-$4.8B Amicus buy

    BioWorld
    Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing